文献速递胸部肿瘤

拉泽替尼对比奥希替尼一线治疗EGFR突变晚期非小细胞肺癌:MARIPOSA随机双盲探索性分析

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
PubMed 文献 · J Thorac Oncol · 2025-07-03

MARIPOSA研究中的探索性分析,在1074例初治EGFR突变晚期非小细胞肺癌患者中随机2:2:1分组,比较拉泽替尼单药(n=216)与奥希替尼单药(n=429)的疗效与安全性;中位随访22.0个月时,两组中位无进展生存期分别为18.5个月与16.6个月(HR=0.98,95%CI 0.79-1.22;p=0.86),拉泽替尼的QT间期延长发生率较低。

要点

  • 拉泽替尼与奥希替尼的中位无进展生存期分别为18.5个月与16.6个月(HR=0.98,95%CI 0.79-1.22;p=0.86)。
  • 可测量病灶患者中,拉泽替尼客观缓解率83% vs 奥希替尼85%,中位缓解持续时间16.6个月 vs 16.8个月。
  • 两组不良事件多为1-2级且常与EGFR抑制相关,拉泽替尼的QT间期延长发生率低于奥希替尼。

核心结论

  • 拉泽替尼的疗效与安全性与奥希替尼相当,包括在预设亚组中。

研究设计与样本

  • MARIPOSA研究中的探索性分析,随机、双盲,比较拉泽替尼与奥希替尼。
  • 1074例参与者按2:2:1随机分配至阿米万他单抗联合拉泽替尼组(n=429)、奥希替尼单药组(n=429)或拉泽替尼单药组(n=216)。
  • 本探索性分析比较拉泽替尼单药(n=216)与奥希替尼单药(n=429)的疗效与安全性。

主要发现

  • 中位随访22.0个月时,拉泽替尼组中位无进展生存期18.5个月 vs 奥希替尼组16.6个月(HR=0.98,95%CI 0.79-1.22;p=0.86)。
  • 预设亚组中两组的无进展生存期结果相当。
  • 基线有可测量病灶的参与者中,客观缓解率拉泽替尼组83% vs 奥希替尼组85%。
  • 确认缓解者的中位缓解持续时间拉泽替尼组16.6个月 vs 奥希替尼组16.8个月。
  • interim分析时两组中位总生存期均未达到(HR=1.00,95%CI 0.73-1.38)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lazertinib is a central nervous system-penetrant, third-generation EGFR tyrosine kinase inhibitor (TKI) that was selected for combination with amivantamab due to its relatively low rates of wild-type EGFR toxicities. In the phase 3 MARIPOSA study, amivantamab plus lazertinib (amivantamab-lazertinib) significantly improved progression-free survival (PFS; p < 0.001) versus osimertinib in participants with treatment-naive EGFR-mutant advanced NSCLC. A lazertinib monotherapy arm was included to assess the contribution of components in the combination. This is the first randomized, double-blind comparison of two third-generation EGFR TKIs, lazertinib and osimertinib. METHODS: In MARIPOSA, 1074 participants were randomized 2:2:1 to receive amivantamab-lazertinib (n = 429), osimertinib monotherapy (n = 429), or lazertinib monotherapy (n = 216). This exploratory analysis compared the efficacy and safety of lazertinib and osimertinib. RESULTS: At a median follow-up of 22.0 months, median PFS was 18.5 months for lazertinib versus 16.6 months for osimertinib (hazard ratio = 0.98, 95% confidence interval: 0.79-1.22; p = 0.86). PFS results were comparable between arms among predefined subgroups. Among participants with measurable disease at baseline, objective response rate was 83% for lazertinib versus 85% for osimertinib, with a median duration of response among confirmed responders of 16.6 months versus 16.8 months, respectively. Median overall survival was not reached for both arms (hazard ratio = 1.00, 95% confidence interval: 0.73-1.38) at the interim analysis. Adverse events for both arms were mostly grades 1 to 2 and frequently related to EGFR inhibition. Lazertinib was associated with lower rates of QT interval prolongation versus osimertinib. CONCLUSIONS: Lazertinib demonstrated comparable efficacy and safety to osimertinib, including in predefined subgroups.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lee SH, Lu S, Hayashi H, et al. Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA. J Thorac Oncol. 2025. PMID: 40617394. doi:10.1016/j.jtho.2025.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。